# A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

> **NCT05720052** · PHASE1,PHASE2 · TERMINATED · sponsor: **MingSight Pharmaceuticals, Inc** · enrollment: 8 (actual)

## Conditions studied

- Relapsed or Refractory B-cell Lymphoma
- Diffuse Large B-cell Lymphoma (DLBCL)
- Follicular Lymphoma (FL)
- Mantle Cell Lymphoma (MCL)
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
- Marginal Zone Lymphoma (MZL)

## Interventions

- **DRUG:** MS-553

## Key facts

- **NCT ID:** NCT05720052
- **Lead sponsor:** MingSight Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-02-06
- **Primary completion:** 2023-11-28
- **Final completion:** 2023-11-28
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** The study is terminated due to major protocol revisions.
- **Last updated:** 2024-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05720052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05720052, "A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05720052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*